Ambry Genetics And PacBio Selected By UCI And GREGoR Consortium To Support Pediatric Mendelian Genomics Research Center Program To Study Rare Diseases
Ambry Genetics And PacBio Selected By UCI And GREGoR Consortium To Support Pediatric Mendelian Genomics Research Center Program To Study Rare Diseases
UCI和GreGor聯盟選中Ambry Genetics和PacBio來支持兒科孟德爾基因組學研究中心研究罕見疾病的計劃
- Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., along with PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced their companies' selection by the University of California, Irvine (UCI) and the GREGoR Consortium (Genomics Research to Elucidate the Genetics of Rare diseases) to support the Pediatric Mendelian Genomics Research Center (MGRC) program to better understand the underlying biology of rare diseases.
- 臨床基因組測試領域的傑出領導者、REALM IDx, Inc. 的子公司Ambry Genetics以及高質量、高精度測序解決方案的領先開發商PacBio（納斯達克股票代碼：PACB）今天宣佈，加州大學爾灣分校（UCI）和格雷戈聯盟（闡明罕見疾病遺傳學的基因組學研究）選擇了他們的公司來支持小兒孟德爾基因組 ICS研究中心（MGRC）計劃旨在更好地了解罕見疾病的潛在生物學。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間